×
About 1,765 results

ALLMedicine™ Ataxia Telangiectasia Center

Research & Reviews  677 results

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04826341

May 20th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Thioredoxin 1 regulates the pentose phosphate pathway via ATM phosphorylation after exp...
https://doi.org/10.1016/j.brainresbull.2022.05.008
Brain Research Bulletin; Wang X, Wang Z et. al.

May 20th, 2022 - Subarachnoid hemorrhage (SAH), a type of hemorrhagic stroke, is a neurological emergency with high morbidity and mortality. Early brain injury (EBI) after SAH is the leading cause of poor prognosis in SAH patients. TRX system is a NADPH-dependent ...

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
https://clinicaltrials.gov/ct2/show/NCT00455325

May 10th, 2022 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-sma...
https://clinicaltrials.gov/ct2/show/NCT04216316

May 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620, VX-970) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Ph...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  14 results

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
https://clinicaltrials.gov/ct2/show/NCT04826341

May 20th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
https://clinicaltrials.gov/ct2/show/NCT00455325

May 10th, 2022 - Metabolic syndrome is one of the most common disorders in industrialized countries. It consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central obesity in the setting of insulin resistance. The syndrome substant...

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-sma...
https://clinicaltrials.gov/ct2/show/NCT04216316

May 3rd, 2022 - PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of carboplatin in combination with berzosertib (M6620, VX-970) and gemcitabine/pembrolizumab, in patients with squamous cell non-small cell lung cancer (Sq-NSCLC). (Lead-in Ph...

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04149145

Jan 24th, 2022 - The primary, secondary, and exploratory objective are to assess the safety of the combination of M4344 and Niraparib in a phase 1 trial of patients with PARP resistant recurrent ovarian cancer; to determine the response rate and percentage of part...

Sarcomas and DDR-Inhibition; a Combined Modality Study
https://clinicaltrials.gov/ct2/show/NCT05116254

Nov 10th, 2021 - Despite improvements in surgery and radiation for soft tissue sarcoma (STS) patients, local relapses remain an important event for these patients. Most STS subtypes are considered radioresistant. Investigations into radiosensitization mediated by ...

see more →

News  13 results

Novel Steroid Therapy May Counter Ataxia Telangiectasia
https://www.medscape.com/viewarticle/971864

Apr 8th, 2022 - SEATTLE — A novel therapy for ataxia telangiectasia that delivers dexamethasone sodium phosphate (DSP) through autologous red blood cells has shown promise in a phase 3 clinical trial. The disease is an autosomal recessive disorder caused by mutat...

Drug Duo Targeting ATR Enzyme Shrinks Small Cell Lung Cancer Tumors
https://www.medscape.com/viewarticle/949638

Apr 21st, 2021 - NEW YORK (Reuters Health) - Combining an ataxia telangiectasia and rad3-related (ATR) inhibitor with topoisomerase 1 (TOP1) yielded an objective response in more than a third of patients with small-cell lung cancer (SCLC) in a phase-2 proof-of-con...

The PARP Inhibitors: Down But Not Out
https://www.onclive.com/view/the-parp-inhibitors-down-but-not-out

Dec 5th, 2020 - Two views of the protein structure of a PARP1 inhibitor complex. Poly(ADP-ribose) polymerase (PARP) inhibitors, particularly Sanofi’s iniparib and AstraZeneca’s olaparib, have elicited both great excitement and significant disappointment in equa...

ATR Inhibitors Offer New Line of Attack on DNA Repair Network
https://www.onclive.com/view/atr-inhibitors-offer-new-line-of-attack-on-dna-repair-network

Dec 5th, 2020 - Cancer cells that manipulate the DNA damage response (DDR) to foster the genomic instability that underlies many of their hallmark processes become heavily reliant on intact pathways for their survival, creating a targetable Achilles heel that can...

Integrating PARP Inhibitors Into the Treatment of Women
https://www.onclive.com/view/integrating-parp-inhibitors-into-the-treatment-of-womens-cancers

Dec 5th, 2020 - Franco Muggia, MD PARP Inhibition in Ovarian Cancer PARP enzymes are involved in a number of DNA repair processes. Tumors with pathogenic BRCA mutations are associated with a deficiency in homologous recombination, a critical double-stranded DNA...

see more →

Patient Education  1 results see all →